- Home
- CAG vs ITCI Comparison
CAG vs ITCI Comparison
Compare CAG & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAG
- ITCI
- Stock Information
- Founded
- CAG 1919
- ITCI 2002
- Country
- CAG United States
- ITCI United States
- Employees
- CAG N/A
- ITCI N/A
- Industry
- CAG Packaged Foods
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- CAG Consumer Staples
- ITCI Health Care
- Exchange
- CAG Nasdaq
- ITCI Nasdaq
- Market Cap
- CAG 12.4B
- ITCI 13.5B
- IPO Year
- CAG N/A
- ITCI N/A
- Fundamental
- Price
- CAG $25.80
- ITCI $128.60
- Analyst Decision
- CAG Hold
- ITCI Buy
- Analyst Count
- CAG 9
- ITCI 13
- Target Price
- CAG $29.89
- ITCI $103.92
- AVG Volume (30 Days)
- CAG 5.9M
- ITCI 2.2M
- Earning Date
- CAG 04-03-2025
- ITCI 02-21-2025
- Dividend Yield
- CAG 5.43%
- ITCI N/A
- EPS Growth
- CAG N/A
- ITCI N/A
- EPS
- CAG 1.03
- ITCI N/A
- Revenue
- CAG $11,928,800,000.00
- ITCI $613,728,000.00
- Revenue This Year
- CAG N/A
- ITCI $48.28
- Revenue Next Year
- CAG $1.43
- ITCI $37.34
- P/E Ratio
- CAG $25.06
- ITCI N/A
- Revenue Growth
- CAG N/A
- ITCI 46.08
- 52 Week Low
- CAG $23.06
- ITCI $63.30
- 52 Week High
- CAG $33.24
- ITCI $128.77
- Technical
- Relative Strength Index (RSI)
- CAG 53.45
- ITCI 83.90
- Support Level
- CAG $23.06
- ITCI $126.88
- Resistance Level
- CAG $25.47
- ITCI $128.19
- Average True Range (ATR)
- CAG 0.66
- ITCI 0.41
- MACD
- CAG 0.09
- ITCI -1.30
- Stochastic Oscillator
- CAG 89.97
- ITCI 91.01
About CAG ConAgra Brands Inc.
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of fiscal 2024 revenue). Most of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. The company primarily sells through the us retail channel, with just 9% of fiscal 2024 revenue coming from international markets and 10% from foodservice.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.